Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
CO-338-014 Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3) III PARP Inhibitor rucaparib
GOG-0225 Can Diet and Physical Activity Modulate Ovarian and Primary Peritoneal Cancer Progression-Free Survival? III Other Not Applicable
NCI-2009-00587 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer III Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor docetaxel; carboplatin; gemcitabine; bevacizumab; paclitaxel
GOG-0281 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer II / III Chemotherapy, Hormonal Therapy, Signal Transduction Inhibitor tamoxifen; topotecan; pegylated-liposomal doxorubicin (PLD); letrozole; paclitaxel; trametinib
UPCC 23814 A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer II Imaging Procedure OTL38
CO-338-017 A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) II PARP Inhibitor rucaparib
UPCC 11814 SIERRA: A PhaSe 1b/2 Study of DemcIzumab Plus PaclitaxEl in Subjects With Platinum Resistant OvaRian, PrimAry Peritoneal or Fallopian Tube Cancer I / II Chemotherapy, Immunotherapy (Monoclonal Antibody) paclitaxel; demcizumab
UPCC 31213 Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers I Immunotherapy CART-meso
UPCC-19809 A Pilot Clinical Trial of Dendritic Cell Vaccine Loaded With Autologous Tumor for Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer 0 Immunotherapy (Vaccine) OC-DC Vaccine
UPCC-10514 Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy Not Specified Radiation Therapy Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-11111 A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
UPCC 08913 A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green I Imaging Procedure Indocyanine Green
UPCC 28813 [18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers 0 Imaging Procedure fluorothymidine F-18
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy Not Applicable
UPCC- 10113 Assessment Of Fertility And Factors Influencing Reproduction And Menopause In BRCA Mutation Carriers. 0 Observational Not Applicable
817628 LDX in the Treatment of Executive Function Difficulties in Women After Oophorectomy Not Specified Supportive Care lisdexamfetamine
UPCC-05809 Ovarian Reserve After Cancer: Longitudinal Effects (ORACLE). A Multicenter Prospective Cohort Study by the Oncofertility Consortium Not Specified Supportive Care Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood or Tissue Collection Not Applicable
UPCC 02813 Autologous Orthotopic Transplantation of Previously Cryopreserved Ovarian Tissue Not Specified Bone Marrow Transplant / Stem Cell Transplant Not Applicable
UPCC-14807 Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen: A Study By The National Physicians Cooperative of the Oncofertility Consortium At Northwestern University IV Supportive Care Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-03909 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer II Signal Transduction Inhibitor palbociclib
UPCC-24213 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies I / II Chemotherapy, Signal Transduction Inhibitor paclitaxel;
CO-338-010 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I / II PARP Inhibitor rucaparib
UPCC 17814 A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies I Signal Transduction Inhibitor BGJ398
UPPC-20512 A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion I Biological Therapy Adenovirus (Adv)-mediated thymidine kinase ; valacyclovir
UPCC-07913 A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors I Chemotherapy, Signal Transduction Inhibitor docetaxel; carboplatin; gemcitabine; paclitaxel;
UPCC 40914 RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers I Radiation Therapy pembrolizumab
CLDE225A2112 A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors I Other warfarin; bupropion
UPCC-29212 A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers I Signal Transduction Inhibitor
CA186-011 A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors I Immunotherapy (Monoclonal Antibody)
CX-839-001 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors I Signal Transduction Inhibitor
UPCC 01614 A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor altiratinib
UPCC-05314 A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects With Adult Solid Tumors I Signal Transduction Inhibitor
UPCC 19913 A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors I Signal Transduction Inhibitor
UPCC-23914 A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable
Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.